Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives

6 Nov 2018

Abstract excerpt

Acute myeloid leukemia (AML) with NPM1 gene mutations is currently recognized as a distinct entity, due to its unique biological and clinical features. We summarize here the results of published studies investigating the clinical application of minimal/measurable residual disease (MRD) in patients with NPM1-mutated AML, receiving either intensive chemotherapy or hematopoietic stem cell transplantation. Several...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30404199
DOI: 10.3390/ijms19113492

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and PerspectivesPMID 30404199Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemiaSemantic proximity Read ↗

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.Semantic proximity Read ↗

Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.Semantic proximity Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.Semantic proximity Read ↗

Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.Semantic proximity Read ↗

Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.Semantic proximity Read ↗

NPM1 for MRD? Droplet Like It's Hot!Semantic proximity Read ↗

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.